MRD negativity and its role as a predictor for CLL patient responses
ASH 2015 highlights in multiple myeloma by Prof. Ola Landgren
The aims of the Genomics England CLL pilot
Why is it important to risk stratify patients in CLL?
Enhancing autologous cellular therapy with ibrutinib in CLL patients
Iris de Weerdt